Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Regulation of the cytotoxic lymphocyte response by macrophage migration inhibitory factor

A cellular, cancer-based technology in the field of modulation of cytotoxic lymphocyte responses by macrophage migration inhibitors

Inactive Publication Date: 2006-10-04
CYTOKINE PHARMASCI
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The mechanisms by which these cytokines inhibit the lytic activity of CTL cells have not yet been fully elucidated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Regulation of the cytotoxic lymphocyte response by macrophage migration inhibitory factor
  • Regulation of the cytotoxic lymphocyte response by macrophage migration inhibitory factor
  • Regulation of the cytotoxic lymphocyte response by macrophage migration inhibitory factor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0046] Materials and methods

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Regulation of expression of CTL activity by macrophage migration inhibitory factor (MIF) is disclosed. In a mouse model using the EL4 tumor, cultured splenocytes from tumor-primed mice secrete high levels of MIF following antigen stimulation in vitro. Parallel splenocytes treated with neutralizing anti-MIF mAb showed a significant increase in CTL response against tumor cells compared to control mAb-treated cultures, with elevated expression of IFN gamma . Histology of tumors from anti-MIF treated animals showed increases in infiltration of both CD4<+> and CD8<+> T cells, as well as apoptotic tumor cells, consistent with observed augmentation of CTL activity in vivo by anti-MIF, which was associated with enhanced expression of the common gamma c chain of the IL-2 receptor that mediates CD8<+>T cell survival. CD8<+> cells of anti-MIF treated tumor-bearing mice showed increased migration into tumors of control mice. Methods for enhancing a CTL response by inhibition of MIF are disclosed.

Description

field of invention [0001] The present invention relates to CD4 + and / or CD8 + Regulate (enhance or reduce) the response of cytotoxic lymphocytes to antigens such as tumor-associated antigens by reducing or increasing the level of macrophage migration inhibitory factor (MIF) before, during or after contact between T lymphocytes and antigens Methods and compositions of the reaction. The present invention also relates to compositions and methods for the prevention and treatment of diseases, especially tumors, by modulating the response of cytotoxic lymphocytes to antigens by means of cell-based immunotherapy. technical background [0002] Data from both laboratory studies and human clinical trials indicate that tumor-associated antigens are sufficient to elicit antitumor cytotoxic lymphocyte (CTL) responses that lead to significant tumor regression (27, 28). In some instances, enhancing CTL cytotoxic activity using a cell-based immunotherapeutic strategy (peptide immunizatio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395A61K38/19A61K48/00A61K35/14A61K39/00A61P35/00A61P43/00C07K16/24C12N5/0783
CPCC07K16/24A61K2039/505A61K39/0011C12N2501/20C12N5/0636A61K2039/5158A61P35/00A61P43/00Y02A50/30A61K39/4611A61K2239/31A61K39/461A61K39/4644A61K2239/38A61K2239/48
Inventor R·阿部R·布卡拉C·梅茨
Owner CYTOKINE PHARMASCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com